Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

[Intravesical radioimmunotherapy of carcinoma in situ of the urinary bladder after BCG failure].

Autenrieth ME, Horn T, Kurtz F, Nguyen K, Morgenstern A, Bruchertseifer F, Schwaiger M, Blechert M, Seidl C, Senekowitsch-Schmidtke R, Gschwend JE, Scheidhauer K.

Urologe A. 2017 Jan;56(1):40-43. doi: 10.1007/s00120-016-0273-4. German.

PMID:
27885456
2.

Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies.

Schwarz T, Seidl C, Schiemann M, Senekowitsch-Schmidtke R, Krause BJ.

Nucl Med Biol. 2016 Jun;43(6):355-9. doi: 10.1016/j.nucmedbio.2016.02.004. Epub 2016 Feb 27.

PMID:
27260776
3.

Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.

Schwarzenböck SM, Schmeja P, Kurth J, Souvatzoglou M, Nawroth R, Treiber U, Kundt G, Berndt S, Graham K, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Dinkelborg L, Wester HJ, Krause BJ.

Mol Imaging Biol. 2016 Jun;18(3):393-401. doi: 10.1007/s11307-015-0901-1.

PMID:
26483088
4.

Non-invasive imaging of implanted peritoneal carcinomatosis in mice using PET and bioluminescence imaging.

Stollfuss J, Landvogt N, Abenstein M, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Wieder H.

EJNMMI Res. 2015 Dec;5(1):125. doi: 10.1186/s13550-015-0125-z. Epub 2015 Sep 4.

5.

Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.

Fazel J, Rötzer S, Seidl C, Feuerecker B, Autenrieth M, Weirich G, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R.

Cancer Biol Ther. 2015;16(10):1526-34. doi: 10.1080/15384047.2015.1071735. Epub 2015 Jul 15.

6.

DCA promotes progression of neuroblastoma tumors in nude mice.

Feuerecker B, Seidl C, Pirsig S, Bruchelt G, Senekowitsch-Schmidtke R.

Am J Cancer Res. 2015 Jan 15;5(2):812-20. eCollection 2015.

7.

Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.

Schwarzenböck SM, Gertz J, Souvatzoglou M, Kurth J, Sachs D, Nawroth R, Treiber U, Schuster T, Senekowitsch-Schmidtke R, Schwaiger M, Ziegler SI, Henriksen G, Wester HJ, Krause BJ.

Mol Imaging Biol. 2015 Apr;17(2):248-56. doi: 10.1007/s11307-014-0782-8.

PMID:
25163420
8.

EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

Mol Ther Nucleic Acids. 2013 Nov 5;2:e131. doi: 10.1038/mtna.2013.58.

9.

Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

J Nucl Med. 2013 Aug;54(8):1450-7. doi: 10.2967/jnumed.112.115493. Epub 2013 Jul 10.

10.

Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation.

Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R.

PLoS One. 2013 May 28;8(5):e64730. doi: 10.1371/journal.pone.0064730. Print 2013.

11.

[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].

Schwarzenböck S, Sachs D, Souvatzoglou M, Schuster T, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler S, Schwaiger M, Senekowitsch-Schmidtke R, Krause BJ.

Nuklearmedizin. 2013;52(4):141-7. doi: 10.3413/Nukmed-0521-12-07. Epub 2013 Feb 11. German.

PMID:
23396481
12.

[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):34-43. doi: 10.1007/s00259-012-2255-0. Epub 2012 Oct 5.

PMID:
23053327
13.

Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus.

Grünwald GK, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Göke B, Holm PS, Spitzweg C.

Gene Ther. 2013 Jun;20(6):625-33. doi: 10.1038/gt.2012.79. Epub 2012 Oct 4.

PMID:
23038026
14.

Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo.

Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R.

Cancer Biol Ther. 2012 Dec;13(14):1425-35. doi: 10.4161/cbt.22003. Epub 2012 Sep 6.

15.

Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.

Vallon M, Seidl C, Blechert B, Li Z, Gilbertz KP, Baumgart A, Aichler M, Feuchtinger A, Gaertner FC, Bruchertseifer F, Morgenstern A, Walch AK, Senekowitsch-Schmidtke R, Essler M.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1886-97. doi: 10.1007/s00259-012-2203-z. Epub 2012 Aug 8.

PMID:
22872310
16.

High molecular mass radioimmunoconjugates are promising for intraperitoneal α-emitter immunotherapy due to prolonged retention in the peritoneum.

Rauch C, Seidl C, Schlapschy M, Skerra A, Morgenstern A, Bruchertseifer F, Senekowitsch-Schmidtke R.

Nucl Med Biol. 2012 Jul;39(5):617-27. doi: 10.1016/j.nucmedbio.2011.12.005. Epub 2012 Mar 3.

PMID:
22381781
17.

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Essler M, Gärtner FC, Neff F, Blechert B, Senekowitsch-Schmidtke R, Bruchertseifer F, Morgenstern A, Seidl C.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):602-12. doi: 10.1007/s00259-011-2023-6. Epub 2012 Jan 12.

PMID:
22237842
18.

Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Klutz K, Willhauck MJ, Dohmen C, Wunderlich N, Knoop K, Zach C, Senekowitsch-Schmidtke R, Gildehaus FJ, Ziegler S, Fürst S, Göke B, Wagner E, Ogris M, Spitzweg C.

Hum Gene Ther. 2011 Dec;22(12):1563-74. doi: 10.1089/hum.2011.041. Epub 2011 Oct 11.

19.

Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.

Klutz K, Willhauck MJ, Wunderlich N, Zach C, Anton M, Senekowitsch-Schmidtke R, Göke B, Spitzweg C.

Hum Gene Ther. 2011 Nov;22(11):1403-12. doi: 10.1089/hum.2010.158. Epub 2011 Jun 28.

20.

Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.

Klutz K, Schaffert D, Willhauck MJ, Grünwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Göke B, Wagner E, Ogris M, Spitzweg C.

Mol Ther. 2011 Apr;19(4):676-85. doi: 10.1038/mt.2010.296. Epub 2011 Jan 18.

21.

177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.

Seidl C, Zöckler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):312-22. doi: 10.1007/s00259-010-1639-2. Epub 2010 Nov 12.

PMID:
21072513
22.

[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.

Krause BJ, Souvatzoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler SI, Senekowitsch-Schmidtke R, Schwaiger M.

Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1861-8. doi: 10.1007/s00259-010-1493-2. Epub 2010 May 30.

PMID:
20512572
23.

Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.

Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

J Nucl Med. 2009 Oct;50(10):1700-8. doi: 10.2967/jnumed.109.065961.

24.

Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.

Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Müller JM, Alke A, Seidl C, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R, Essler M.

PLoS One. 2009 May 27;4(5):e5715. doi: 10.1371/journal.pone.0005715.

25.

Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.

Müller SA, Holzapfel K, Seidl C, Treiber U, Krause BJ, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1434-42. doi: 10.1007/s00259-009-1117-x. Epub 2009 Apr 8.

PMID:
19352653
26.

Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.

Seidl C, Port M, Apostolidis C, Bruchertseifer F, Schwaiger M, Senekowitsch-Schmidtke R, Abend M.

Invest New Drugs. 2010 Feb;28(1):49-60. doi: 10.1007/s10637-008-9214-4. Epub 2009 Jan 13.

PMID:
19139817
27.

Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment.

Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, zum Büschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK.

Mol Imaging Biol. 2008 Nov-Dec;10(6):349-55. doi: 10.1007/s11307-008-0162-3. Epub 2008 Aug 14.

PMID:
18704591
28.

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.

Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, Henning TD, Wels WS, Uherek C, Rummeny EJ, Daldrup-Link HE.

Nucl Med Biol. 2008 Jul;35(5):579-88. doi: 10.1016/j.nucmedbio.2008.02.006. Epub 2008 May 2.

PMID:
18589302
29.

Effects of irradiation on the [Methyl-3H]choline uptake in the human prostate cancer cell lines LNCaP and PC3.

Holzapfel K, Müller SA, Seidl C, Grosu AL, Schwaiger M, Senekowitsch-Schmidtke R.

Strahlenther Onkol. 2008 Jun;184(6):319-24. doi: 10.1007/s00066-008-1799-1.

PMID:
18535808
30.

Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.

Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, Essler M.

Clin Cancer Res. 2008 Jun 1;14(11):3555-61. doi: 10.1158/1078-0432.CCR-07-4647.

31.

[Demonstration of angiogenesis and the effect on an antiangiogenetic therapy with 99mTc labeled erythrocytes].

Zengel P, Bodenstein C, Senekowitsch-Schmidtke R, Weber WA.

Nuklearmedizin. 2008;47(3):104-9. German.

PMID:
18493689
32.

Tc-Glutathione Complex (Tc -GSH) : Labelling, Chemical Characterization and Biodistribution in Rats.

Baba K, Moretti JL, Weinmann P, Senekowitsch-Schmidtke R, Ercan MT.

Met Based Drugs. 1999;6(6):329-36. doi: 10.1155/MBD.1999.329.

33.

The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ, Knapp WH, Göke B, Morris JC, Spitzweg C.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1272-81. doi: 10.1007/s00259-008-0775-4. Epub 2008 Apr 11.

PMID:
18404268
34.

Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.

Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C.

Gene Ther. 2008 Feb;15(3):214-23. Epub 2007 Nov 8.

PMID:
17989705
35.

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.

Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. Epub 2007 Sep 22.

PMID:
17891393
36.

213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe.

Seidl C, Port M, Gilbertz KP, Morgenstern A, Bruchertseifer F, Schwaiger M, Röper B, Senekowitsch-Schmidtke R, Abend M.

Mol Cancer Ther. 2007 Aug;6(8):2346-59.

37.

Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression.

Willhauck MJ, Sharif Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Göke B, Morris JC, Spitzweg C.

J Clin Endocrinol Metab. 2007 Nov;92(11):4451-8. Epub 2007 Aug 14.

PMID:
17698909
38.

Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.

Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC, Spitzweg C.

Breast Cancer Res Treat. 2008 May;109(2):263-72. Epub 2007 Jul 18.

PMID:
17636401
39.

213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice.

Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, Schwaiger M, Senekowitsch-Schmidtke R.

Cancer Sci. 2007 Aug;98(8):1215-22. Epub 2007 Jun 11.

40.

Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. Epub 2007 Jan 6.

PMID:
17206415
41.

The sensitivity of the alkaline comet assay in detecting DNA lesions induced by X rays, gamma rays and alpha particles.

Rössler U, Hornhardt S, Seidl C, Müller-Laue E, Walsh L, Panzer W, Schmid E, Senekowitsch-Schmidtke R, Gomolka M.

Radiat Prot Dosimetry. 2006;122(1-4):154-9. Epub 2006 Dec 19.

PMID:
17182604
42.

Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells.

Stöber B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):932-9. Epub 2006 Apr 8.

PMID:
16604346
43.

CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.

Saur D, Seidler B, Schneider G, Algül H, Beck R, Senekowitsch-Schmidtke R, Schwaiger M, Schmid RM.

Gastroenterology. 2005 Oct;129(4):1237-50.

PMID:
16230077
44.

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.

Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7070s-7074s.

45.

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Seidl C, Schröck H, Seidenschwang S, Beck R, Schmid E, Abend M, Becker KF, Apostolidis C, Nikula TK, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R.

Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):274-85. Epub 2004 Oct 2.

PMID:
15791436
46.

Positron emission tomography as a tool for translational research in oncology.

Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M.

Mol Imaging Biol. 2004 Jul-Aug;6(4):214-24. Review.

PMID:
15262237
47.

Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide.

Kuhnast B, Bodenstein C, Haubner R, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M, Weber WA.

Nucl Med Biol. 2004 Apr;31(3):337-44.

PMID:
15028246
48.

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Beyer GJ, Miederer M, Vranjes-Durić S, Comor JJ, Künzi G, Hartley O, Senekowitsch-Schmidtke R, Soloviev D, Buchegger F.

Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):547-54. Epub 2004 Jan 14.

PMID:
14722680
49.

Comparison study of oxygen-induced MRI-signal changes and pO2 changes in murine tumors.

Weissfloch L, Peller M, Weber J, Feldmann HJ, Senekowitsch-Schmidtke R, Tempel K, Coderre JA, Molls M, Reiser M.

Adv Exp Med Biol. 2003;530:461-5.

PMID:
14562741
50.

Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.

Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, Apostolidis C, Nikula T, Kremmer E, Schwaiger M, Senekowitsch-Schmidtke R.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3922S-8S.

Supplemental Content

Loading ...
Support Center